- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Cresset Asset Management Boosts Stake in Bio-Techne
Biotechnology firm sees increased institutional investment as stock price fluctuates
Published on Mar. 4, 2026
Got story updates? Submit your updates here. ›
Cresset Asset Management LLC, an investment management firm, increased its position in Bio-Techne Corp (NASDAQ:TECH) by 4.4% during the third quarter of 2025, according to a recent SEC filing. The fund now owns 668,117 shares of the biotechnology company's stock, valued at $37.17 million as of the filing date.
Why it matters
The increase in Cresset's stake in Bio-Techne reflects ongoing institutional investor interest in the company, which develops and manufactures high-quality reagents, instruments, and services for the research, diagnostic, and bioprocessing markets. This comes as Bio-Techne's stock price has fluctuated over the past year, providing potential buying opportunities for investors.
The details
According to the filing, Cresset Asset Management acquired an additional 28,344 shares of Bio-Techne during the third quarter, bringing its total position to 668,117 shares. This represents approximately 0.43% of the company's outstanding stock. The investment firm cited Bio-Techne's strong product portfolio and market position as factors behind the increased stake.
- Cresset Asset Management filed its 13F report for the third quarter of 2025 on March 4, 2026.
The players
Cresset Asset Management LLC
An investment management firm that has increased its stake in biotechnology company Bio-Techne Corp.
Bio-Techne Corp
A global life sciences company that develops, manufactures, and sells high-quality reagents, instruments, and services for the research, diagnostic, and bioprocessing markets.
The takeaway
The increase in Cresset Asset Management's position in Bio-Techne reflects ongoing institutional investor interest in the company, which has seen its stock price fluctuate over the past year. This suggests that Bio-Techne's strong product portfolio and market position continue to attract the attention of major investors.
Minneapolis top stories
Minneapolis events
Mar. 5, 2026
Minnesota Timberwolves vs. Toronto RaptorsMar. 5, 2026
Jason Isbell and the 400 UnitMar. 5, 2026
Ruel - Kicking My Feet Tour




